Jason Glanz, PhD

Senior Investigator

Jason GlanzJason M. Glanz, PhD, is a Senior Investigator at the Institute for Health Research. Dr. Glanz's research focuses on vaccine safety, vaccine acceptance, substance abuse, and epidemiological methods.

Dr. Glanz earned his Master of Science degree in biostatistics from the University of Massachusetts Amherst and completed his doctoral training in epidemiology at the Colorado School of Public Health. He is a co-principal investigator for the Vaccine Safety Datalink (VSD), a nationwide Centers for Disease Control and Prevention-funded project that examines the safety of vaccines and leads research efforts to develop risk communication tools to reduce parental vaccination concerns. He is also co-leading a large randomized pragmatic trial examining the impact and safety of co-dispensing the overdose reversing medication naloxone with opioid prescriptions.

Dr. Glanz is an Associate Clinical Professor of Epidemiology in the Department of Epidemiology at the University of Colorado School of Public Health.


Selected Research

  • Vaccine Safety Datalink (VSD) - Infrastructure Activities

    The major goal of this project is to evaluate the safety of currently licensed vaccines in the U.S. To accomplish this goal, we provide electronic clinical data to the weekly dynamic data files and lead specific vaccine safety studies within the VSD.
    Funder: Centers for Disease Control & Prevention
    Study End Date: 9/27/2022

  • Methods for Safety Evaluation of Vaccination Schedules

    The objective of this project is to develop epidemiological and statistical methods to study the safety of the recommended childhood immunization schedule.
    Funder: National Institute of Allergy & Infectious Diseases
    Study End Date: 7/31/2018

  • The REDIVAC Study-Reducing Delay in the Vaccination of Children

    The objective of this study is to develop and test a vaccine tailored messaging intervention for parents.
    Funder: National Institute of Child Health & Human Development
    Study End Date: 3/31/2019

  • The Safety and Impact of Expanded Access to Naloxone in Health Systems

    Our study will examine the impact and safety of expanded access to naloxone, an effective opioid antidote which reverses opioid overdose, for patients prescribed opioids for pain in two large and diverse health systems.
    Funder: National Institute on Drug Abuse
    Study End Date: 4/30/2021

  • Assessing the Safety and Effectiveness of Opioid Tapering in Large Health Systems.

    This study will use epidemiological methods to examine the safety and effectiveness of opioid prescribing practices across three large health systems.
    Funder: National Institute on Drug Abuse
    Study End Date: 12/31/2022